| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $0 | 0 | 0 |
Sells | $775,091 | 18 | 100 |
| Yaffe Kristine | director | 0 | $0 | 1 | $1,440 | $-1,440 |
| Hammond Paula | director | 0 | $0 | 1 | $32,998 | $-32,998 |
| Wong-Sarad Grace | Principal Accounting Officer | 0 | $0 | 8 | $71,346 | $-71,346 |
| Kenkare-Mitra Sara | President and Head of R&D | 0 | $0 | 2 | $105,692 | $-105,692 |
| Berkley Neil Lindsay | Principal Financial Officer | 0 | $0 | 3 | $144,225 | $-144,225 |
| Rosenthal Arnon | Chief Executive Officer | 0 | $0 | 3 | $419,389 | $-419,389 |
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.
Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $775,091 worth of Alector, Inc. stock.
On average, over the past 5 years, insiders at Alector, Inc. have bought $0 and sold $9.24M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.
| 2026-04-16 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 1,820 0.0017% | $2.65 | $4,823 | -13.33% | |
| 2026-03-10 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 1,000 0.0011% | $2.65 | $2,650 | -6.30% | |
| 2026-03-03 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 3,367 0.0029% | $2.08 | $7,012 | +4.74% | |
| 2026-03-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 81,864 0.0655% | $2.12 | $173,822 | 0.00% | |
| 2026-03-02 | Sale | Berkley Neil Lindsay | CFO & Chief Business Officer | 29,649 0.0237% | $2.12 | $62,954 | 0.00% | |
| 2026-03-02 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 8,071 0.0065% | $2.12 | $17,138 | 0.00% | |
| 2026-02-26 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 4,079 0.0036% | $2.50 | $10,198 | -13.67% | |
| 2025-12-05 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 4,753 0.0047% | $1.21 | $5,751 | +68.03% | |
| 2025-12-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 104,347 0.1036% | $1.12 | $116,827 | +78.51% | |
| 2025-12-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 41,687 0.0414% | $1.12 | $46,673 | +78.51% | |
| 2025-12-03 | Sale | Berkley Neil Lindsay | Chief Bus Ofcr & Interim CFO | 37,261 0.037% | $1.12 | $41,717 | +78.51% | |
| 2025-12-03 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 8,056 0.008% | $1.12 | $9,019 | +78.51% | |
| 2025-09-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 51,562 0.0491% | $2.50 | $128,740 | -20.85% | |
| 2025-09-02 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 23,638 0.0225% | $2.50 | $59,019 | -20.85% | |
| 2025-09-02 | Sale | Berkley Neil Lindsay | Principal Financial Officer | 15,842 0.0151% | $2.50 | $39,554 | -20.85% | |
| 2025-09-02 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 5,910 0.0056% | $2.50 | $14,756 | -20.85% | |
| 2025-08-26 | Sale | Hammond Paula | director | 14,000 0.0129% | $2.36 | $32,998 | -12.71% | |
| 2025-06-20 | Sale | Yaffe Kristine | director | 1,000 0.001% | $1.44 | $1,440 | +35.37% | |
| 2025-06-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 52,087 0.0505% | $1.34 | $69,713 | +43.48% | |
| 2025-06-02 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 23,890 0.0232% | $1.34 | $31,974 | +43.48% |
| Rosenthal Arnon | Chief Executive Officer | 2338176 2.106% | $3.67M | 0 | 24 | |
| Kenkare-Mitra Sara | President and Head of R&D | 501652 0.4518% | $787,593.64 | 0 | 12 | |
| Berkley Neil Lindsay | CFO & Chief Business Officer | 344660 0.3104% | $541,116.20 | 0 | 3 | |
| Wong-Sarad Grace | Principal Accounting Officer | 104645 0.0943% | $164,292.65 | 0 | 8 | |
| Yaffe Kristine | director | 95409 0.0859% | $149,792.13 | 0 | 2 | |
| Hammond Paula | director | 74909 0.0675% | $117,607.13 | 0 | 2 | |
| MCGUIRE TERRANCE | 10853817 9.776% | $17.04M | 0 | 2 | ||
| Polaris Venture Management Co. VI, L.L.C. | 10 percent owner | 10853817 9.776% | $17.04M | 0 | 2 | |
| GORDON CARL L | 10434976 9.3988% | $16.38M | 1 | 0 | +10.01% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 1906718 1.7174% | $2.99M | 1 | 17 | +10.01% |
| Oney Sabah | Chief Business Officer | 573918 0.5169% | $901,051.26 | 0 | 11 | |
| King Robert | Chief Development Officer | 529295 0.4767% | $830,993.15 | 0 | 11 | |
| Romano Gary | Chief Medical Officer | 332977 0.2999% | $522,773.89 | 0 | 11 | |
| GRASSO MARC | Chief Financial Officer | 296072 0.2667% | $464,833.04 | 0 | 10 | |
| Paul Robert | Chief Medical Officer | 234319 0.2111% | $367,880.83 | 0 | 37 | |
| SULIMAN SHEHNAAZ | President and COO | 102598 0.0924% | $161,078.86 | 0 | 4 | |
| Yu Calvin | Vice President, Finance | 76686 0.0691% | $120,397.02 | 0 | 8 | |
| Wehner David M. | director | 44621 0.0402% | $70,054.97 | 1 | 0 | <0.0001% |
| SCHELLER RICHARD H | director | 35000 0.0315% | $54,950.00 | 0 | 4 |
$22,693,451 | 105 | 8.15% | $171.89M | |
$7,147,964 | 34 | 24.77% | $155.52M | |
$47,438,336 | 33 | -21.38% | $181.44M | |
$18,752,549 | 33 | -28.39% | $149.57M | |
$448,999,793 | 15 | -19.99% | $197.47M | |
$4,701,608 | 14 | -4.34% | $165.17M | |
$1,037,470 | 13 | 78.00% | $198.11M | |
$19,167,169 | 10 | 28.48% | $192.1M | |
$344,394 | 8 | -22.26% | $164.64M | |
$22,090,972 | 7 | -3.49% | $156.33M | |
$164,999,952 | 5 | -44.44% | $197.73M | |
$36,049,976 | 5 | -3.82% | $174.75M | |
$32,007,657 | 4 | -45.65% | $193.92M | |
$16,003,671 | 3 | 55.38% | $173.82M | |
Alector, Inc. (ALEC) | $32,289,200 | 3 | -5.46% | $174.31M |
$193,101 | 3 | -25.20% | $192.48M | |
$12,498 | 2 | 39.61% | $184.53M | |
$12,750 | 2 | -39.73% | $154.39M | |
$86,200 | 1 | -19.57% | $169.77M |
| Increased Positions | 67 | +35.83% | 38M | +50.82% |
| Decreased Positions | 80 | -42.78% | 27M | -36.8% |
| New Positions | 25 | New | 23M | New |
| Sold Out Positions | 40 | Sold Out | 9M | Sold Out |
| Total Postitions | 174 | -6.95% | 85M | +14.01% |
| Fmr Llc | $23,228.00 | 13.93% | 15.18M | +182,960 | +1.22% | 2025-09-30 |
| Blackrock, Inc. | $11,013.00 | 6.6% | 7.2M | -775,607 | -9.73% | 2025-09-30 |
| Rtw Investments, Lp | $10,696.00 | 6.41% | 6.99M | +7M | New | 2025-09-30 |
| Vanguard Group Inc | $9,233.00 | 5.54% | 6.03M | +46,955 | +0.78% | 2025-09-30 |
| Merck & Co., Inc. | $5,425.00 | 3.25% | 3.55M | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $3,631.00 | 2.18% | 2.37M | +202,597 | +9.34% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $3,343.00 | 2.01% | 2.19M | -3M | -55.18% | 2025-09-30 |
| Geode Capital Management, Llc | $2,848.00 | 1.71% | 1.86M | -120,810 | -6.09% | 2025-09-30 |
| State Street Corp | $2,654.00 | 1.59% | 1.73M | +24,777 | +1.45% | 2025-09-30 |
| Eversept Partners, Lp | $2,278.00 | 1.37% | 1.49M | -497,347 | -25.04% | 2025-09-30 |